C4 Therapeutics Inc (NASDAQ:CCCC) price on Thursday, April 10, fall -6.92% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.21.
A look at the stock’s price movement, the close in the last trading session was $1.30, moving within a range at $1.17 and $1.32. The beta value (5-Year monthly) was 3.124. Turning to its 52-week performance, $8.08 and $1.09 were the 52-week high and 52-week low respectively. Overall, CCCC moved -44.75% over the past month.
C4 Therapeutics Inc’s market cap currently stands at around $85.90 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
The average forecast suggests down to a -2.93% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 21.49M, representing a -39.60% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CCCC is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 1 recommend CCCC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CCCC’s current price about -30.41% and -50.31% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 24.63, while 7-day volatility ratio is 15.99% and 10.13% in the 30-day chart. Further, C4 Therapeutics Inc (CCCC) has a beta value of 3.15, and an average true range (ATR) of 0.18. Analysts have given the company’s stock an average 52-week price target of $12, forecast between a low of $12 and high of $12. Looking at the price targets, the low is -891.74% off current price level while to achieve the yearly target high, price needs to move -891.74%. Nonetheless, investors will most likely welcome a -891.74% jump to $12 which is the analysts’ median price.
If we refocus on C4 Therapeutics Inc (NASDAQ:CCCC), historical trading data shows that trading volumes averaged 0.99 over the past 10 days and 1.43 million over the past 3 months. The company’s latest data on shares outstanding shows there are 70.63 million shares.
The 20.11% of C4 Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 83.17% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.17 million on 2025-03-14, giving us a short ratio of 5.8. The data shows that as of 2025-03-14 short interest in C4 Therapeutics Inc (CCCC) stood at 1393.0000000000002 of shares outstanding, with shares short rising to 8.06 million registered in 2025-02-14. Current price change has pushed the stock -66.39% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CCCC stock continues to rise going into the next quarter.
